title: Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.
abstract: In the National Cancer Institute's Second Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Biology of Relapse discussed recent advances in understanding some of the host-, disease-, and transplantation-related contributions to relapse, emphasizing concepts with potential therapeutic implications. Relapse after hematopoietic stem cell transplantation (HSCT) represents tumor escape, from the cytotoxic effects of the conditioning regimen and from immunologic control mediated by reconstituted lymphocyte populations. Factors influencing the biology of the therapeutic graft-versus-malignancy (GVM) effect-and relapse-include conditioning regimen effects on lymphocyte populations and homeostasis, immunologic niches, and the tumor microenvironment; reconstitution of lymphocyte populations and establishment of functional immune competence; and genetic heterogeneity within the malignancy defining potential for clonal escape. Recent developments in T cell and natural killer cell homeostasis and reconstitution are reviewed, with implications for prevention and treatment of relapse, as is the application of modern genome sequencing to defining the biologic basis of GVM, clonal escape, and relapse after HSCT.
authors.affiliation: Experimental Transplantation Immunology Branch, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland.
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Gress
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Miller
authors.forename: Minoo
authors.initials: M
authors.lastname: Battiwalla
authors.forename: Michael R
authors.initials: MR
authors.lastname: Bishop
authors.forename: Sergio A
authors.initials: SA
authors.lastname: Giralt
authors.forename: Nancy M
authors.initials: NM
authors.lastname: Hardy
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kröger
authors.forename: Alan S
authors.initials: AS
authors.lastname: Wayne
authors.forename: Dan A
authors.initials: DA
authors.lastname: Landau
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Wu
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D054547:National Cancer Institute (U.S.); D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000628:therapy; D009369:Neoplasms / Q000601:surgery*; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous; D014481:United States
keywords: Allogeneic; Biology; Prevention; Relapse; Stem cell transplantation; Treatment
references.citation: J Immunol. 1996 Jun 15;156(12):4609-16
references.pmid: 8648103
references.citation: Cancer Res. 2009 Jun 1;69(11):4894-903
references.pmid: 19487300
references.citation: Nat Genet. 2006 Apr;38(4):468-73
references.pmid: 16565718
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13081-6
references.pmid: 18723673
references.citation: Science. 2002 Mar 15;295(5562):2097-100
references.pmid: 11896281
references.citation: Hematology Am Soc Hematol Educ Program. 2012;2012:143-51
references.pmid: 23233573
references.citation: N Engl J Med. 1995 Jan 19;332(3):143-9
references.pmid: 7800006
references.citation: Blood. 2002 Aug 1;100(3):1014-8
references.pmid: 12130516
references.citation: Nat Med. 2011 Sep 18;17(10):1290-7
references.pmid: 21926977
references.citation: Blood. 2004 Jul 1;104(1):281-9
references.pmid: 15010368
references.citation: Biol Blood Marrow Transplant. 2013 Dec;19(12):1661-9
references.pmid: 24018393
references.citation: Cytotherapy. 2011 Jan;13(1):98-107
references.pmid: 20849361
references.citation: Immunol Rev. 1997 Jun;157:61-72
references.pmid: 9255622
references.citation: Cancer Cell. 2011 Dec 13;20(6):810-7
references.pmid: 22137795
references.citation: Haematologica. 2013 Mar;98(3):346-52
references.pmid: 23065508
references.citation: Bone Marrow Transplant. 2003 Jul;32(2):177-86
references.pmid: 12838283
references.citation: J Immunol. 1998 Jul 15;161(2):571-7
references.pmid: 9670929
references.citation: N Engl J Med. 2011 Dec 29;365(26):2497-506
references.pmid: 22150006
references.citation: Blood. 1997 May 15;89(10):3700-7
references.pmid: 9160675
references.citation: Biol Blood Marrow Transplant. 2014 Jan;20(1):4-13
references.pmid: 24018392
references.citation: Blood. 1994 Oct 1;84(7):2221-8
references.pmid: 7919339
references.citation: Cancer Cell. 2011 Dec 13;20(6):695-7
references.pmid: 22172718
references.citation: Science. 2008 Nov 28;322(5906):1377-80
references.pmid: 19039135
references.citation: Blood. 2005 Dec 15;106(13):4370-6
references.pmid: 16131567
references.citation: Cancer Cell. 2009 Aug 4;16(2):137-48
references.pmid: 19647224
references.citation: Blood. 2012 Aug 2;120(5):1060-6
references.pmid: 22529291
references.citation: PLoS One. 2012;7(1):e30422
references.pmid: 22276195
references.citation: Blood. 1997 Nov 1;90(9):3789-98
references.pmid: 9345067
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: Mol Cancer Ther. 2012 Dec;11(12):2674-84
references.pmid: 23075808
references.citation: Blood. 2010 Oct 7;116(14):2411-9
references.pmid: 20581313
references.citation: Nature. 2005 Aug 4;436(7051):709-13
references.pmid: 16079848
references.citation: Biol Blood Marrow Transplant. 2008 Mar;14(3):290-300
references.pmid: 18275895
references.citation: N Engl J Med. 2012 Aug 30;367(9):805-16
references.pmid: 22931314
references.citation: Biol Blood Marrow Transplant. 2003 Mar;9(3):198-205
references.pmid: 12652471
references.citation: Blood. 2011 Sep 8;118(10):2784-92
references.pmid: 21757615
references.citation: Nat Med. 2011 Mar;17(3):313-9
references.pmid: 21386835
references.citation: J Clin Invest. 2010 May;120(5):1479-93
references.pmid: 20389017
references.citation: Blood. 2012 Mar 15;119(11):2665-74
references.pmid: 22180440
references.citation: Science. 1976 Oct 1;194(4260):23-8
references.pmid: 959840
references.citation: Blood. 2010 Oct 7;116(14):2438-47
references.pmid: 20595516
references.citation: J Clin Invest. 2005 Apr;115(4):930-9
references.pmid: 15776111
references.citation: Blood. 2005 Apr 15;105(8):3051-7
references.pmid: 15632206
references.citation: Nature. 2009 Jan 29;457(7229):557-61
references.pmid: 19136945
references.citation: Nat Rev Cancer. 2012 Apr 12;12(5):335-48
references.pmid: 22495321
references.citation: N Engl J Med. 2011 Dec 1;365(22):2055-66
references.pmid: 22129252
references.citation: Science. 2002 May 17;296(5571):1323-6
references.pmid: 11950999
references.citation: Cancer Immunol Immunother. 2010 Nov;59(11):1739-44
references.pmid: 20680271
references.citation: Nature. 2012 Jan 11;481(7382):506-10
references.pmid: 22237025